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Abstract Nitrogen supply is pivotal for the maintenance of
life. Amino acids can be utilized to synthesize both glucose
and lipids. The opposite, i.e., production of amino acids
from either one of them, is not possible in the absence of
other amino acids as donors of nitrogen. The quality of
amino acid content in protein has been re-evaluated
recently, and the relevance of essential amino acids has
been repeatedly underlined. Essential amino acid require-
ments in different mammals are not identical, and ratios
among them should be taken into account when projecting
an efficient formulation. Recent research has demonstrated
that genes respond to different qualities and quantities of
nutritional supply, and increased provision of essential
amino acids increases lifespan in animal experiments
through mitochondriogenesis and maintenance of elevated
rates of synthesis of anti-oxidant molecules. Moreover,
genetic expression of key controllers of synthesis, like
mTOR, may be particularly important for understanding
skeletal muscle maintenance. Losses of muscle mass and
impaired immune function are related to reduced protein
supply, and there is increasing evidence that regular
essential amino acid intake as part of an oral diet is
effective in reversing muscle catabolism, promoting muscle
anabolism, and restoring immunological function. There-
fore, the use of amino acids as supplements to diet would
be expanding in the near future. Is this safe? Few data are
available on amino acid toxicity, and only one essential
amino acid may be considered to have clinically relevant
toxicity: methionine, because it is transformed into a toxic
intermediate, homocysteine, when cysteine synthesis is
required by metabolic needs. Matching of stoichiometric
ratios between methionine and cysteine may solve the
problem of supplying sufficient amounts of sulfur to the
body. Arginine and glutamine are two non-essential amino
acids than can become “conditionally essential” because of
elevated needs during pathological conditions, and metab-
olism may not be able to maintain their concentrations at
sufficient levels to match metabolic requirements. Chronic
exogenous arginine supplementation has not proven to
exert positive clinical effects in different trials, and
sequential articulation of the knowledge of introduction of
arginine-driven transcriptional, translational, and epigenetic
adaptations may give us a key for interpreting those
puzzling results.
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Muscle.Definition of life
1 Introduction
In 1944, Schrödinger proposed that life could be based
on the laws of physics [1]. Many attempts to define life
have been proposed since then. All attempts, however,
received major criticism, but at least, there is general
agreement on three characteristics typical for all living
systems: self-reproduction (permitting preservation of
information), mutation (permitting evolution), and metab-
olism (permitting selection of a system for a certain
function) [2].
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role of amino acids (AA) in human metabolism, life is the
huge energetic cost of maintaining concentrated amounts of
atoms, mostly carbon, oxygen, hydrogen, and nitrogen.
These atoms are enclosed in the limited environment that
we identify as cells, tissues, organs, and organisms. Life
sciences are the study of the complex organization that
allows maintenance of continuous production of this
energy. In mammals, energy is derived mostly from breaking
down carbon–carbon bonds present in some nutrients. Such
nutrients need to be introduced in adequately large amounts,
and thus are identified as macro-nutrients (from ancient
greek—macro = big, large). Organic molecules, particularly
AAs, were present on earth long before life developed [3],
and life eventually became possible by the adaptation of
activities and functions according to nutritional opportunities
available in the environment. In contrast to other organisms
such as plants, mammals do not possess the genetic
capability to utilize inorganic nitrogen for the maintenance
of life. Thus, we depend on constant nitrogen supply for
growth, development, and survival [4].
2 Skeletal muscles as an amino acids reservoir
Therefore, conditions that are accompanied by a dysbalance
between supply and requirements ultimately yield depletion
of the main AA reservoir in the body, skeletal muscle [5, 6].
Sarcopenia, wasting, and cachexia are the clinical
demonstration that AAs are important substrates to the first
priority of life—production of energy. Adequate nutrition,
on the other hand, could provide sufficient amounts of
carbohydrates and lipids to spare excessive degradation of
AAs for energy metabolism, and providing enough essen-
tial amino acids (EAA) to promote and maintain synthesis
[7]. In this context, the relevance of the concept that only
EAAs promote and maintain muscle synthesis [8] cannot be
stressed enough with regards to the fullness of its
implications [9]. EAA availability controls the balance
between synthesis and degradation of human muscle, EAA
availability is the limiting factor for maintaining synthesis
of new proteins. The ratio among degradation and synthesis
is fundamental for maintaining efficient protein-based
activities and functions, and changing the dimensions of
AA supply deeply alters this balance [10].
3 The role of essential amino acids in muscle metabolism
Concentrations of AAs in human cells are regulated by the
expression of AA transporters, which are controlled and
upregulated by increasing EAA availability [11]. Availabil-
ity of all the EAAs in adequate stoichiometric ratios is not
the only limiting factor for protein synthesis, but EAAs are
also signaling molecules and gene expression modulators.
Thus, prolonged supplementation of EAAs increases basal
and post-insulin stimulation of key signals of the insulin/
AKT/mTOR pathway, and is prompted to re-establish
responsiveness to post insulin IRS1 degradation in muscles
of aging rats [12]. Another feature accompanying aging,
loss of mitochondria, is reversed by EAA supplementation
through activation of Sirt-1 dependent mitochondrial-
biogenesis [13]. This feature is paralleled by improved
oxygen supply by restoration of expression of endothelial
nitric oxide synthase in key tissues such as the kidneys
[14]. As a consequence of these effects, chronic EAA
supplementation increased lifespan when compared to ad
libitum normal diet or calorie restriction [13].
In humans, different studies have shown that EAAs are
efficient in promoting protein synthesis independent of age
[15] and in reducing muscular catabolism even in
prolonged bed rest in the elderly [16]. Dietary EAA
supplementation was also successful in other pathological
conditions characterized by the presence of a sarcopenia-
wasting-cachexia syndrome, like in chronic obstructive
pulmonary disease, in which supplementation of EAAs
improved protein synthesis, physical strength, and arterial
pO2 [17].
4 The knot of calculating nitrogen needs by urea
synthesis
It is important to discuss potential mistakes that may
originate from calculating nitrogen needs independent of
EAAs requirements [7, 18]. Calculation of nitrogen balance
provides the gold standard for the evaluation of matching
nitrogen demand and supply [19]. It is widely accepted to
calculate nitrogen balance by using urea synthesis and
analyzing the relationship between oral protein intake and
urea excretion in the urine. In that context, nitrogen (N)
balance (B) is estimated according to the formula:
NB ¼ protein intake=6:5   urinary urea þ 4 ðÞ
Protein intake/6.5 expresses the protein nitrogen content
in grams, and 4 is the conventional sum of nitrogen losses
due to incomplete nitrogen digestion. Such losses include
fecal losses and daily nitrogen losses through other sources
(i.e., hair, nails, skin desquamation, sweat, etc.). Positive
balance means nitrogen retention, indicating that protein
intake has been sufficient to provide more nitrogen than is
lost. Negative balance means that protein intake does not
match the needs, and catabolism of muscle proteins may
become prevalent. Therefore, evaluation of nitrogen bal-
ance is mainly based on dynamics of urea synthesis. But,
although nitrogen balance remains a pivotal clinical tool, a
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about the genetic control of arginase expression, the
enzyme that synthesizes urea, although dynamics of urea
synthesis have not been critically revised. Arginase exists in
two isoenzymes (or isoforms), whose expression is con-
trolled by different genes located on different chromo-
somes. Arginase I is a cytosolic enzyme and comprises
about 98% of the high arginase activity present in liver, but
it accounts for only 50% of arginase activity in the kidneys
and other organs. In these organs, the remaining arginase
activity is represented by the mitochondrial isozyme
arginase, arginase II. Both isoforms are quite ubiquitous,
although expressed in different ratios in different cell types
[20]. Arginase I is also present in red blood cells and in
plasma, but the role of red blood cell arginases in degrading
arginine and thus regulating availability of arginine for
nitric oxide (NO) synthesis has never been investigated in
much detail. What is really important is that genetic
expression and the level of activity of arginases is induced
by arginine concentrations, and thus the rate of exogenous
arginine supply determines arginase expression and the rate
of urea synthesis and arginine plasma levels [21]. These
facts imply that the same nutritional nitrogen supply may
still yield different arginase expression, dependent on the
amounts of arginine provided by food. Consequently, a
more or less prominent activity on arginine catabolism and
urea production are induced according to arginine content.
This is a quite disturbing point, because Allison
identified the reference protein ovalbumin in 1956, suitable
to provide humans with adequate amounts of EAAs, and all
enteral or parenteral nutritional formulations have ever
since used stoichiometric ratios of AAs similar to those
contained in the reference protein. In fact, Allison was very
foresighted, and he also underlined the fact that ovalbumin
had a content of non-essential AAs (like arginine) that are
rather high, but probably necessary mostly to spare EAAs
for essential organs by oviparous. Indeed, non-essential
AAs could be used for less important structures such as
feathers [22].
Moreover, EAAs are not necessary all in the same
amount. As an example, the daily requirements for leucine
and those for tryptophan are not the same. Therefore, it
could be calculated that only five EAAs match 70% of total
nitrogen EAA requirements: leucine, isoleucine, valine,
histidine, and lysine [23]. In different studies dealing with
protein or AA effects, a formulation of AA like that
presented in Fig. 1 was used to perform protocols
evaluating possible diabetogenic effects of amino acids
[24]. This formulation mimicked ovalbumin AA content. If
we calculate the number of molecules contained in the
molecular weight of any AA provided by that formulation
(i.e., the stoichiometric ratio) for just three non-essential
AAs like arginine, alanine and glutamine as well as the
number of molecules of those five EAAs that cover 70% of
human needs, we have the dramatic sensation that we are
providing enormous numbers of molecules that are not
suitable for promoting protein syntheses [8]. However, all
of them directly or indirectly (e.g., by being used for
energy) contribute first to arginine then to urea synthesis
[25]. Arginine is also implicated in the development of
insulin resistance by nitrogen introduction [26, 27].
In patients with chronic kidney disease, EAA supple-
mentation proved to be more effective than ovalbumin-
similar formulations in promoting synthesis of visceral
proteins without altering urea production [28]. Similar
findings were observed in diabetic patients affected by
chronic heart failure [29, 30], and in intensive care unit
patients after neurosurgery [31]. Therefore, we should
always ask ourselves, if increases in urea excretion are a
sign of an ameliorated nitrogen balance, or if such increases
simply mirror an inadequate EAA availability as part of
excessive non-essential AA supply, i.e., the failure of
supply to match requirements and needs.
In my opinion, dynamical evaluation of changes in
synthesis by repeated monitoring of plasma concentrations
of visceral proteins (albumin, transferrin, prealbumin, or
rethinol-binding protein) would be the best clinical param-
eter for general practitioners to evaluate their patients. A
prerequisite is that the liver has a sufficiently large working
cell mass. All patients with albumin plasma levels below
normal should be considered at risk of protein malnutrition
independent of any other medical condition. Such finding
should prompt further clinical investigation. Albumin has a
long half-life (about 3 weeks), but other proteins like
transferrin (half-life about 1 week) or prealbumin (better
identified as trans-thyretin, or TTR—half-life of about
48 h) or rethinol-binding protein (RBP—half-life of about
12 h) can be used to monitor more accurately and at shorter
intervals success or failure of treatment options. In any
case, any patient with plasma albumin levels of 3.2 g/L
should be considered severely malnourished and possibly
cachectic and treated aggressively. Indeed, low plasma
albumin levels are predictors of poor prognosis in different
pathological conditions [32, 33]. The only limit of the use
of those parameters in evaluating malnutrition is that the
integrity of liver function is conditioning for syntheses.
5 Toxicity of amino acids
There are very few papers dealing with upper limits of safe
AA supply or toxicity of AAs in healthy humans [34, 35]
Most, if not all, deal with alterations connected with single
AAs [36, 37]. A PubMed search under “amino acids safe
upper level of intake” yielded just 12 papers. In my
opinion, methionine is the only EAA that can be considered
J Cachexia Sarcopenia Muscle (2011) 2:75–80 77toxic. Experimental studies dating back to 1971 identified
methionine as the “most toxic” AA. Indeed, when methi-
onine was added to diet in a ratio of 5%, it produced the
largest depression of growth in rats fed 10% casein-rich
diets, and when compared to any other AA it was
particularly efficient in depressing growth as well as
protein, DNA and RNA content in liver of animals
receiving the same amount of any of the 18 AAs examined.
Interestingly, the L-form was even more toxic than the D-
form. Moreover, increasing the percentage of casein fed
with diet blunted the toxicity of any other AA. On the
contrary, methionine supplementation toxicity was most
inefficiently reduced even by increasing intake of proteins
up to 50% of total food intake [38]. Most of methionine
toxicity is dependent on the intermediate metabolite formed
when cysteine and/or cystine have to be synthesized from
methionine to match metabolic requirements. This metabolic
intermediate, homocysteine (Hcys), may have different toxic
effects. A most interesting one is that Hcys seems to control
increased expression of β-hydroxy-β-methylglutaryl coen-
zyme A (HMG-CoA) reductase in arteries walls [39]. Indeed,
in conditions associated with chronic hyperhomocysteine-
mia, atheromatous lesions of carotid arteries are peculiarly
frequent [40]. But other possible negative effects have been
ascribed to increased oxidative damage [41] and impairment
of nitric oxide (NO) production [42]. Increased homocystei-
nization of proteins in cells may lead to increased athero-
sclerosis either by eliciting both inflammation and cell death
and/or auto-immunoresponse due to anti-N-Hcys-protein
antibodies [43].
Sulfur-containing AAs are indispensable for life. Among
these, methionine is the only one considered essential. In
order to prevent excess Hcys synthesis, two to three
molecules of cysteine for any molecule of methionine
supplied would be the best way to match bodily require-
ments and safety aspects [44]. Arginine is one of the non-
essential AAs that can become “conditionally essential”,
i.e., not synthesized in adequate amounts during highly
demanding pathological conditions. It is the indispensable
substrate for NO production, but the VINTAGE study
showed that exogenous chronic supply was potentially
deleterious in patients after myocardial infarction [45].
However, acute administration elicits increased NO pro-
duction even if endothelial intracellular arginine concen-
trations are deemed to be largely sufficient to totally
saturate NO synthases, a phenomenon known as “the
arginine paradox” [46].
Chronic arginine supplementation proved to increase
mortality in patients after myocardial infarction; thus, we
must answer in the affirmative, but its supplementation is
still recommended in different pathological conditions [47].
Should arginine be considered toxic? Although literature
about the arginine paradox is immense, very few papers
have discussed the possible reasons for its toxicity in
specific pathological situations [21]. I believe that this is a
classic example of how important toxicogenomic studies
may become. Indeed, exogenous arginine supplementation
elicits a late (48 h) and progressive increased expression of
arginase, the enzyme producing urea and competing with
NO synthases for arginine. Thus, the more arginine is
Fig. 1 Typical formulation of amino acids used in different clinical
studies, formulation inspired to ovalbumin amino acids content.
Proportions based on 100 mg, L-forms. This formulation contains
both essential (EAA) and non-essential amino acids (NEAA). There is
prevalence of non-essential amino acids on essential ones. But if the
weight would be transformed in number of molecules, the content in
just two non-essential amino acids, alanine, and arginine (alanine,
230 mmol; arginine, 66 mmol; sum, 296 mmol) is enormously
superior to those of the five essential amino acids that are required to
cover 70% of human nitrogen needs (leucine, 56 mmol; isoleucine,
39 mmol; valine, 50 mmol; histidine, 33.5 mmol; lysine, 38 mmol;
sum, 219.5 mmol). Alanine and arginine have significant interferences
with glucose oxidative metabolism
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mised recycling back to arginine of citrulline formed by NO
production, as well as in those presenting with insulin
resistance and excess beta-oxydation, acute supplementa-
tion would elicit improved acute NO production. Chronic
supplementation, on the other hand, would progressively
impair peripheral NO production. Similar considerations
may be valid for glutamine, an AA also “conditionally
essential” in sepsis, but exogenous administration has not
always proven safe [48]. Also, glutamine toxicogenomics
should be evaluated, because exogenous glutamine sup-
presses glutamino-synthase expression [49]. Therefore, it
should be taken into account that patients may become
totally dependent on exogenous glutamine supply for
maintenance of sufficiently elevated glutamine plasma
concentrations in order to maintain leucocyte and immune
function [50]. At physiological food concentrations, the
largest part of oral glutamine intake is disposed of by
enterocytes during absorption and by splanchnic bed at first
passage, and mostly used for energy [51]. Thus, we are
challenging the hypothesis that a progressive discontinua-
tion of glutamine supplementation should be planned, and
correct queuing could be done most safely if EAAwould be
supplied on a daily basis. Supplementation by EAA should
be performed until genetic expression of glutamine syn-
thetic pathway would be restored and adequate glutamine
synthesis from EAA and intermediates of TCA would be
achieved [52].
6 Concluding remarks
EAAs are indispensable for the maintenance of life under
normal and pathological conditions. Genetic expression
modifications induced by increasing supply of EAA
suggest beneficial effects of chronically modifying the ratio
with non-essential AAs.
Therefore, supplementing diet with EAA is an efficient
method to increase efficiency of nitrogen supply and
maintaining integrity of the largest reservoir of amino
acids, skeletal muscles, while optimizing urea synthesis.
The suggestion to the skilled clinician could be to take into
account the chance to use a 1–1 . 5g / 1 0k g
−1 day
−1
supplementation with EAA in any patient with plasma
albumin lower than 3.5 g/L
−1, because those are the
amounts used with success in clinical published studies.
Patients not responding to such supplementation within 2–
3 weeks or with worsening albumin values, or those
presenting with albumin values lower than 3.2 g/L
−1 should
be referred to the clinical nutritionist's intensive care. For
general clinical and prognostic purposes, we have no better
method for understanding the sufficient supply of EAAs
other than monitoring synthesis of visceral proteins.
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